BMS abandons CytomX's next-gen Yervoy hopeful in surprise move
12 Mar 2024
Phase 2
Bristol Myers Squibb has decided not to continue the development of BMS-986288, a potential successor to its blockbuster anti-CTLA-4 drug Yervoy (ipilimumab), beyond the current Phase II study.
The company was partnered on the next-generation checkpoint inhibitor with CytomX Therapeutics, which made the disclosure during its earnings call after having been notified by Bristol Myers Squibb on March 6.
"This unexpected decision followed a broad internal portfolio review at BMS. We continue to work with BMS to gain more visibility on the data from this programme and the factors that led to this decision," stated CytomX CEO Sean McCarthy. The news dragged down company shares as much as 19% in after-hours trading Monday, and remained down about 15% by mid-day Tuesday.
BMS-986288 is a probody composed of a modified version of Yervoy and linked to a proprietary masking peptide that minimises binding to CTLA-4 in normal tissues, potentially resulting in lower systemic toxicity.
Bristol Myers Squibb was running a mid-stage trial of BMS-986288 alone and in combination with Opdivo (nivolumab) in close to 500 patients with advanced solid tumours. Primary completion was set for next month, according to the study's entry on ClinicalTrials.gov.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
Targets
Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.